If you weren't already aware, GLP-1 weight loss drugs from the likes of Novo Nordisk and Eli Lilly and Company are the biotech sphere's new craze, managing to rope in seasoned analysts who appear to be salivating at the prospect of billions of dollars in additional revenue streams. Yet, the hype seems to have lost some of its patina recently. TD COWEN: “.. surprised to see two months in a row of declines in the number of people who describe themselves as current users of GLP-1s. .. We believe this is a function of capacity constraints .. Penetration rates may […]
Read full article at https://wccftech.com/the-penetration-of-glp-1-weight-loss-drugs-declines-for-the-second-consecutive-month-but-analysts-say-this-is-a-blip/
WccftechContinue reading/original-link]